Illiasul Ibad/X
Aug 24, 2025, 18:21
Illiasul Ibad: How Clinical Trials Revolutionized ANCA Vasculitis Treatment from Cyclophosphamide to Rituximab
Illiasul Ibad, Rheumatologist at Christian Medical College, Vellore, shared a post on X:
“How clinical trials revolutionized ANCA vasculitis maintenance – from cyclophosphamide to rituximab, this is the journey of evidence, one trial at a time.
Facts. Timelines. Game-changers.
A must-read for every physician, rheumatologist, nephrologist, pulmonologist, and ophthalmologist. This is how science shaped the standard of care.
Special thanks to George Deva Raja for the image design.”
Stay updated with Hemostasis Today.
-
Sep 4, 2026, 18:49Børge Nordestgaard: Lp(a) Remains a Risk Factor Across the Lifespan
-
Sep 4, 2026, 18:22Tareq Abadl: The Clinical Meaning of C3 and C4
-
Sep 4, 2026, 18:16How Mutant p53 Hijacks VWF Expression in Tumor Cells – JTH
-
Sep 4, 2026, 18:08Simon Kraler: Can the Adrenomedullin System Predict Cardiogenic Shock Before It Happens?
-
Sep 4, 2026, 17:56Maxime Dely: Why Every Blood Donation Matters
-
Sep 4, 2026, 17:28Shinya Goto: When Cardiovascular Risk Gets Lower, RCTs Get Harder
-
Sep 4, 2026, 16:55New Orleans Is Calling ASH26 Is Near
-
Sep 4, 2026, 16:48ESC Congress 2026 – My Top 20 Lipidology Highlights Shaping the Future of Cardiovascular Prevention – Pablo Corral
-
Sep 4, 2026, 16:38Felice Gragnano։ Turning Cardiovascular Risk Into Action